Business Context and Reporting Period
This Form 8-K filing by Vivos Therapeutics, Inc. (Nasdaq: VVOS) reports corporate governance and compensation actions taken by the Board of Directors on September 7, 2024, with the report dated September 12, 2024. The filing details the approval of a new equity incentive plan and amended employment agreements for the Chief Executive Officer and Chief Financial Officer, subject to stockholder approval at the upcoming Annual Meeting.
Key Financial Metrics and Compensation Details
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt. Instead, it discloses specific compensation figures and equity allocations:
- Equity Plan Size: The proposed 2024 Omnibus Equity Incentive Plan authorizes 1,600,000 shares of Common Stock for future awards.
- Contingent Option Grants: A total of 1,020,487 options were granted contingent on stockholder approval of the new plan.
- R. Kirk Huntsman (CEO): 315,421 ISOs
- Bradford Amman (CFO): 149,533 ISOs
- All Other Employees/Consultants: 555,533 options
- Exercise Price: Contingent options were granted at $2.62 per share (closing price on September 6, 2024).
- Base Salary Increases (Effective Jan 1, 2025):
- CEO: Increased to $450,000 (from $389,595).
- CFO: Increased to $320,000 (from $259,648).
- Target Cash Bonus: CEO at 75% of base salary; CFO at 50% of base salary.
Material Changes Versus Prior Period
The filing outlines significant changes to the company's compensation framework compared to prior arrangements:
- Plan Replacement: The 2024 Omnibus Plan is designed to replace the Amended and Restated 2019 Stock Option and Stock Issuance Plan. Upon stockholder approval, the 2019 Plan will be superseded, and any unused shares in the 2019 Plan will be retired.
- Employment Agreement Updates: New agreements for the CEO and CFO supersede the October 8, 2020 agreements, introducing higher base salaries and revised severance structures.
- Severance Enhancements:
- Termination without Cause/Good Reason: Entitles executives to 12 months of base salary severance and full vesting of unvested equity.
- Change in Control (CIC) + Termination: Severance increases to 24 months of base salary, with full equity vesting.
- Death/Disability: Severance reduced to 6 months of base salary, with full equity vesting.
Guidance, Outlook, Risks, and Contingencies
Contingencies: The approval of the 2024 Omnibus Plan and the associated contingent option grants are strictly conditional upon stockholder approval at the 2024 Annual Meeting. If stockholders do not approve the plan, the contingent options will be null and void, and the 2019 Plan will remain in effect until expiration.
Outlook: Management anticipates the 1,600,000 shares allocated to the new plan will sustain the program for several years, though this could change based on merger and acquisition activity.
Risks and Restrictions: The amended employment agreements include a 24-month non-compete clause following termination for any reason. The filing notes that the descriptions provided are summaries and are qualified by the full text of the agreements, which will be filed as exhibits to the Form 10-Q for the period ended September 30, 2024.
Key Facts for Investor Verification
- Verify the outcome of the stockholder vote on the 2024 Omnibus Plan at the Annual Meeting, as the 1,020,487 contingent options and the new plan's effectiveness depend entirely on this approval.
- Review the full text of the Amended Employment Agreements (expected in the Q3 2024 Form 10-Q) to understand specific definitions of "Cause," "Good Reason," and "Change in Control."
- Monitor the dilution impact of the 1,600,000 shares authorized under the new plan and the immediate grant of over 1 million options.
- Confirm the effective date of the salary increases (January 1, 2025) and the associated cash flow implications for the company.